Healthcare / BiotechnologyNasdaqGM
$6.53
-0.37 (-5.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-62.3M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$308M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-142.2%
↓Gross Margin
61.5%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-70.4%
FCF CAGR
—
FCF margin
-11149.6%
FCF / Net income
0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $559000.0 · net income $-88.6M · FCF $-62.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $559000.00 | $559000.00 | $43.3M | $31.6M | $21.7M |
| Net Income | $-88.6M | $-88.6M | $-45.3M | $-54.2M | $-50.3M |
| EBITDA | $-89.2M | $-89.2M | $-62.7M | $-63.8M | $-60.4M |
| EPS | -1.89 | -1.89 | -0.99 | -1.47 | -1.56 |
| Gross Margin | 61.5% | 61.5% | 72.7% | 59.3% | 37.8% |
| Operating Margin | -16056.0% | -16056.0% | -146.4% | -203.5% | -281.9% |
| Net Margin | -15851.9% | -15851.9% | -104.7% | -171.4% | -232.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 |
| Current Ratio | 9.83 | 9.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-62.3M | $-62.3M | $-67.9M | $-49.5M | $-57.6M |
| Returns | |||||
| ROE | -142.2% | -142.2% | -33.8% | -246.6% | -188.4% |
| Valuation | |||||
| P/B | 4.95 | 4.95 | 2.55 | 30.22 | 17.79 |
| Growth & Yield | |||||
| Revenue Growth | -98.7% | -98.7% | 36.7% | 46.1% | — |
| EPS Growth | -90.9% | -90.9% | 32.7% | 5.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+11.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.99 → -1.89
Residual
+11.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.